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primary treatment goals were reductions of the risk of bone complications and 
associated bone pain.
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SCreeNiNg guideliNeS ANd CANCer StAge: eArly FiNdiNgS From 
mediCAre
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Objectives: Clinical guidelines now are commonly used in many settings, though 
the impact of these guidelines on real world practice remains less clear. The 
USPSTF recently dropped recommendations for breast cancer screening among 
women aged 75+ years. Prior studies using survey data suggest that the guideline 
revision had no effect on screening behavior. Using registry and claims data, we 
assessed changes in screening patterns, and stage at diagnosis, among female 
Medicare beneficiaries aged 75+years compared with 65-74 years. MethOds: 
We examined 2003-11 biennial mammography screening rates using national 
Medicare fee-for-service claims (20% random sample), and linked SEER registry-
Medicare claims databases. Using linear regression models with a patient-level 
fixed effect, we estimated the change in proportion of subjects receiving screening 
over time (as well as the rate of incident cases of earlier vs. later stage cancer), 
among subjects aged 75+yo compared with younger subjects, i.e., a difference-in-
difference design. Results: We find a decrease in screening rate among women 
aged 75+ years after the revision (2011 vs. 2003-2008, and the difference in changes 
compared with younger women was 13.2% (95%CI:13.1-13.3%). Similarly, we find 
a relative decrease in the population rate of incident cases of earlier-stage cancer 
(0.12%, 95%CI: 0.07-0.17), increases in later-stage cancer. cOnclusiOns: With the 
guideline revision, there were relative decreases in screening rates among women 
aged 75+ years, compared with younger women. There also was a breast cancer 
stage shift, with more later-stage cancers and fewer earlier-stage cancers detected. 
Future evaluations on survival are needed. Moreover, as health insurance plans 
increasing link benefit designs with guidelines, the likelihood that guidelines will 
impact practice patterns could grow.
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Objectives: To compare the treatment patterns and resulting quality adjusted 
life year (QALY) in patients of Head & Neck cancers under private payment scheme 
(PPS) and government scheme (GS). MethOds: In a prospective study treatment 
orders of patients on chemotherapy for head & neck cancers were reviewed and 
patients were interviewed for six treatment cycles to assess treatment patterns in 
an oncology hospital having dedicated wards for patients under GS. Direct medi-
cal cost, indirect medical cost and non-medical costs associated with treatment 
were calculated for patients under PPS and GS and were compared. EQ-5D-5L 
instrument was administered to assess patient utility with treatment during 
each cycle. Results: A total of 104 patients (n= 49 under PPS, n= 55 under GS) 
were enrolled in the study after obtaining their informed consent. Majority of the 
patients under PPS were on Paclitaxel based regimen (63%) followed by primary 
protocol ((Docetaxel+ Cyclophosphamide+ Fluorouracil, (8%)). Most of the patients 
under GS were treated with Cisplatin with radiation therapy (82%) and none of the 
eligible patients under GS had privilege of treatment with primary protocol due 
to limited budget. Treatment compliance to NCCN guidelines for patients under 
PPS and GS was 89% and 58% respectively. Common adverse events like vomiting, 
constipation, neutropenia, fatigue and myalgia were higher in patients under GS 
than PPS. Average cost of treatment for PPS and GS per cycle was US $125 and US $30 
respectively. QALY gained by patients under PPS and GS after six cycles was 0.024 
and 0.014 respectively and the difference was found to be statistically significant 
(p< 0.05). cOnclusiOns: Treatment patterns in patients under PPS were well com-
pliant to NCCN guidelines. Limited budget of government scheme in a developing 
country does not allow clinicians to prescribe required anti-cancer medicines and 
supportive care. Patients under GS can be benefited with more utility with additional 
increment in the budget.
reSPirAtory-relAted diSorderS – Clinical outcomes Studies
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Objectives: This signal detection pharmacovigilance activity aims to determine 
if treatment with desloratadine is associated with more than expected report-
ing of torsade de pointes and electrocardiogram QT prolongation (TQP) events 
in real-world settings. MethOds: Adverse event reports submitted to the FDA 
Adverse Event Reporting System were used (cumulative to June 2014), and Multi-
item Gamma Poisson Shrinker disproportionality analysis algorithm was applied 
to calculate Empirical Bayes Geometric Mean (EBGM) and corresponding 95%CI as 
association metrics. Desloratadine was defined by generic name, and ventricular 
tachycardia events were defined as structured MedDRA queries of Preferred Terms 
denoting to TQP. Reporting profile was compared to loratadine, the parent drug of 
desloratadine. Arrhythmogenic antihistamines, astemizole and terfenadine, were 
used as positive controls. Results: Seventeen reports of TQP were submitted 
for desloratadine corresponding to 59% male users (mean age 44 years), and 17% 
and 35% of TQP events were life-threatening and lead to patient hospitalization, 
demographics, comorbidities, therapy type, treatment initiator, and concomitant 
medications were descriptively examined across the EU-5 and by individual coun-
try. Results: A total of 64,932 patients from Germany (24,577), France (12,574), 
Italy (11,676), UK (8,427), and Spain (7,698) were included. The majority were male 
(64%, except Germany was 50%), > 56 years (70%), and had chemo-radiation (91%). 
Comorbidities were similar across countries, except COPD (5%, whereas Spain was 
19%) and Cardiac Dysfunction (4%, whereas Germany was 21%). Except in the UK, 
temozolomide was used, on average, for 82% of front-line patients with treatment 
being initiated by a radiologist (58%) or medical oncologist (23%). In the UK, temo-
zolomide was used for 65% of front-line patients and was initiated by a radiologist 
90% of the time. Surgical procedures including Excision of Lesion, Craniotomy, and 
Lobectomy were performed, on average, in 67% of patients, except in France (44%). 
However, French patients were more likely to have a Burr Hole Biopsy (43%) versus 
the other 4 countries (average of 20%). Frequently used concomitant medications 
were corticosteroids (3-fold variation across EU-5), anti-emetics (5-fold variation), 
and gastrointestinal medications (on average 20%). cOnclusiOns: The common 
front-line treatment for glioblastoma was found to be surgery followed by temozolo-
mide chemotherapy, consistent with guidelines. However, there was some variation 
across countries with regards to the type of surgery, comorbidities, chemotherapy 
initiator, and concomitant medications. Further study is needed to comprehensively 
characterize glioblastoma treatment patterns in the EU-5.
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Objectives: To examine bone pain and BTA treatment patterns in patients with 
BMs from BC in real-world setting in Europe. MethOds: The study was conducted 
using the Adelphi Breast Cancer Disease-Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 385 oncologists from 6 European countries 
(UK, Germany, France, Italy, Spain, and Belgium). Each physician completed a patient 
record form (PRF) for 10 patients being treated for advanced BC that captured the 
following information: presence of BMs, current pain state, current analgesic use, 
BTA treatment, and reasons behind BTA treatment decisions. Results: A total 
of 1376 patients with BM from BC were identified. At the time of survey (an aver-
age of 11 months after diagnosis of BMs), 47% of the patients experienced mild 
pain; and 20% had moderate/severe pain. The majority of the patients (96%) with 
pain took analgesic drugs to manage pain, which included 28% (n= 260) patients 
treated with strong opioids (e.g. morphine, oxycodone etc.). Of them, 59% (154/260) 
still experienced moderate/severe bone pain. Among the patients with BMs, 88% 
(n= 1210) were treated with a BTA. Of them, 81% (n= 979) received treatment within 
3 months of BMs diagnosis. Reasons for BTA treatment initiation within 3 months 
of BMs were “bone pain” (34%), “high risk of bone complications” (31%), “number of 
BMs” (13%), “location of BMs” (8%) and “prior history of bone complications” (7%). 
Reasons for not treating patients with BTAs were “recent diagnosis” (40%), “low bone 
complication risk” (17%), “focus on treating primary tumor” (10%), and “short life 
expectancy” (10%). cOnclusiOns: Bone pain is the main symptom encountered 
by patients with BMs from BC. Most of these patients treated with strong opioids 
still experienced moderate/severe bone pain. The majority of patients with BMs 
received BTAs; primary treatment goals were reductions of bone pain and risk of 
bone complications.
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Objectives: To examine bone pain and BTA utilization in patients with BMs from 
PC in real-world setting in Europe. MethOds: This study was conducted using 
the Adelphi Prostate Cancer Disease Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 241 oncologists and 103 urologists in 6 
European countries (UK, Germany, France, Italy, Spain, and Belgium). Patients’ 
current pain state, current analgesic use, BTA treatment, and reasons for BTA 
treatment data were extracted from the patient record forms (PRFs) completed 
by the physicians. Results: A total of 3608 PRFs were collected including 1931 on 
PC patients with BMs. At the time of survey (an average of 15.2 months from BMs 
diagnosis), 41% patients experienced mild pain; and 29% had moderate/severe 
bone pain. The majority of the patients (96%) with pain took analgesics to manage 
pain, including 29% (n= 387) patients who were treated with strong opioids (e.g. 
morphine, oxycodone etc.). Of these patients, 73% (284/387) still had moderate/
severe pain. Among the patients with BMs, 74% (n= 1437) were treated with a BTA, 
and BTA treatment occurred within 3 months of BMs diagnosis in 72% (n= 1036) 
of them. Reasons for BTA treatment initiation within 3 months of BMs were “bone 
pain” (40%), “high risk of bone complications” (29%), “number of BMs” (11%), “loca-
tion of BMs” (8%) and “prior history of bone complications” (5%). Reasons for not 
treating patients with BTA were “recent diagnosis” (36%), “low bone complication 
risk” (22%), and “focus on treating primary tumor” (8%). cOnclusiOns: Bone pain 
is the major symptom encountered by patients with BMs from PC. The majority 
of these patients treated with strong opioids still experienced moderate/severe 
bone pain. Approximately three quarters of patients with BMs received BTAs; 
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Objectives: To estimate the efficacy and safety of glycopirronium-indacaterol 
(GLN/IND) as maintenance therapy for moderate to severe chronic obstructive pul-
monary disease (COPD) compared to other first-line treatments, through a system-
atic review and meta-analysis. MethOds: A detailed search was performed in eight 
electronic databases (MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, 
Cochrane Database of Abstracts of Reviews of Effects (DARE), LILACS, Cochrane 
Central Register of Randomized Controlled Trials, WHO International Clinical Trials 
Registry Platform, ClinicalTrials.gov) searching for clinical trials that compared effi-
cacy and/or safety of glycopirronium (GLN) alone or GLN/IND as first-line drugs 
for moderate to severe COPD. Seven functional and quality of life outcomes were 
collected. An expert panel supported and validated the methodology. Finally, a 
meta-analysis was performed when the homogeneity of the information permit-
ted. Results: 14.349 references were originally identified, 13.253 were left after 
eliminating duplicates, and were reviewed by two researchers; 112 full-text articles 
were retrieved, and finally 13 provided useful information and were included in the 
analysis. Studies comparing tiotropium (TIO) with GLN didn’t show statistically 
significant differences in efficacy or safety. Studies comparing GLN/IND against TIO, 
showed statistically significant results, favoring GLN/IND, for “trough FEV1 “ (a func-
tional indicator), as well as for, both quality of life scales (Transition Dyspnea Index 
TDI and Saint Georges Respiratory Questionnaire SGRQ). With respect to safety, GLN/
IND and all first drugs have a similar profile. cOnclusiOns: We conclude that GLN/
IND is more effective than other first-line drugs in the management of moderate to 
severe COPD, with a similar safety profile.
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Objectives: The primary objective of this study was to update the results of the 
examination of GOLD 2011 COPD management recommendation implementation 
among the Czech respiratory specialists with respect to the patients’ classification. 
The secondary objective was to explore effect of a misclassification on the use of 
inhaled corticosteroids (ICS). MethOds: Multicenter cross-sectional study was con-
ducted among COPD specialists, consisting of general questionnaire and patient-
specific forms. A subjective classification into the GOLD 2011 groups as practiced by 
the healthcare professionals was examined and then compared with the objective 
classification achieved by rigorous software-computed classification. Results: There 
were significant differences between patient’s objective and subjective GOLD clas-
sification. The ratio in percent of the patients was as follows: A 26.4/14.9, B 20.0/28.4, 
C 12.7/24.3 and D 40.9/30.8. The best match was found between D category, followed 
by B, A and C. About 45% of the doctors assign patients to the GOLD category incor-
rectly disregarding whether they were using GOLD classification or not. One sixth of 
the patients received inhalation corticosteroids, half of those incorrectly. About four 
percent of the patients received iPDE4, half of those incorrectly. More than two thirds 
of the patients (75.9%) received LABA in any combination or alone. About half of the 
patients (57.4% and 46.3%) received LAMA or ICS in any combination or alone. Three 
most common objectively assign phenotypes were emphyzematic, bronchitic and 
repeated exacerbations phenotypes. The same results were obtained for subjectively 
assign phenotypes. The most common objective overlap phenotypes were bronchitic 
& emphyzematic, bronchitic & repeated exacerbations and bronchitic & emphyzem-
atic & repeated exacerbations overlap phenotypes. The same results were obtained 
for subjective phenotypes. cOnclusiOns: Despite high awareness of the GOLD 2011 
guidelines, its implementation is insufficient. Doctors therefore both assign patients 
to the wrong GOLD category and prescribe inadequate drugs, specifically ICS.
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Objectives: To assess the comparative efficacy and safety of monoclonal antibodies 
and a tyrosine-kinase inhibitor for severe or uncontrolled asthma, using a Bayesian 
network meta-analysis. MethOds: A systematic literature review was conducted 
according to NICE guidelines. Outcomes of interest included asthma control ques-
tionnaire (ACQ) score, asthma exacerbations and discontinuations due to adverse 
events (AE). Identified studies assessed mepolizumab, lebrikizumab, omalizumab and 
masitinib. Networks of evidence were based on treatment- and dose-specific nodes 
except for masitinib (results were only reported for pooled doses). Interpretation of 
results was based on absolute differences/ratios and Bayesian probabilities for treat-
ments to perform better than others (P), where P≤ 15% indicated a smaller effect and 
P≥ 85% a larger effect. Vague prior distributions were used. Results: 8/6/3 studies 
reported results at 16/26/52 weeks respectively. Analyses indicated that active treat-
ments and placebo had comparable ACQ score reductions (D) at 16 weeks; at 52 weeks, 
omalizumab performed better than mepolizumab 75mg and 750mg (D= -0.25 and -0.20 
respectively, P≥ 86%), and was comparable to mepolizumab 250mg (D= -0.13, P= 75%). 
All active treatments performed better than placebo. In terms of asthma exacerba-
tions, at 16 weeks, omalizumab was comparable to masitinib (OR= 1.30, P= 64%) and 
performed better than placebo, while masitinib was comparable to placebo (OR= 0.60, 
P= 76%). At 26 weeks, omalizumab performed better than placebo. At 16 and 26 weeks, 
active treatments and placebo had comparable discontinuations due to AE rates. 
At 52 weeks, mepolizumab 75mg had lower discontinuations due to AE rates than 
mepolizumab 750mg, and was comparable to other treatments. Omalizumab, mepoli-
zumab 250mg, 750mg and placebo were comparable. cOnclusiOns: This network 
meta-analysis of asthma treatments suggested that omalizumab had greater ACQ 
score reductions at 52 weeks than mepolizumab 75mg and 750mg but was compa-
respectively. For loratadine, a total of 147 TQP reports were submitted, correspond-
ing to 61% male users (mean age 51 years), and 8% and 36% of TQP events were fatal 
and life-threatening, respectively; 65% of reported events contributed to patient 
hospitalization. On average, desloratadine and loratadine users used 3 concomi-
tant medications at the time of TQP occurrence. Reporting of TQP for deslorata-
dine users was more than expected (EBGM= 1.70; 95%CI= 1.13-2.48), but a stronger 
signal was found for loratadine users (EBGM= 3.65; 95%CI= 3.18-4.17). Astemizole 
and terfenadine were associated with significant signals of TQP (EBGM= 20.1; 
95%CI= 17.3-23.3 and EBGM= 15.0; 95%CI= 13.6-16.4, respectively). cOnclusiOns: 
Anti-allergy treatment with desloratadine might be associated with TQP. A non-
arrhythmogenic antihistamine might be an alternative therapy in patients at 
risk of ventricular tachycardias. Cardiac conduction monitoring might be recom-
mended in desloratadine users.
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Objectives: 1 To estimate the prevalence of ADRs including serious/fatal ADRs 
and clinical manifestations. 2 To analyze cost of treatment for serious and fatal 
ADRs. MethOds: the prevalence of AdRs: A cross-sectional descriptive study. 
Data was collected from electronic database in Vajira Hospital during 1 January 
2012-31 December 2013 from inpatient and outpatient departments. Those 
patients had experienced with those ADRs from other hospitals or been diag-
nosed for ADRs by physicians or pharmacists at Vajira Hospital. costs of treat-
ment for serious and fatal AdRs (baht per event) were direct medical costs. 
Costs included drug costs which were obtained from the median price from the 
Drug and Medical Supply Information Center, Ministry of Public Health, cost of 
admissions to hospital and laboratory cost, which were obtained from the unit 
cost of the standard cost for HTA.The Costs were evaluated from the resources 
being used in medical records and verify by physicians. Results: There were 
737 identified ADRs events which consisted of ADRs type A (42events,6%) and 
ADRs Type B (695 events, 94%). Amlodipine was responsible for the most com-
mon ADRs type A (n= 7,17%) for swollen feet while antimicrobial agents, cef-
triaxone was responsible for the most common ADRs type B (n= 69, 10%). 
Majority of manifestation of drug allergies were skin systems (n= 615, 83%).
Serious and Fatal ADRs were showed for 42 events (6%),which antimicrobial 
agents were responsible for the most common causes (ceftriaxone n= 4) followed 
by NSAIDs (Ibuprofen n= 3)and anticonvulsants (Phenytoin n= 4).Direct medi-
cal cost for the treatment of Serious and Fatal ADRs was about 41,000 baht per 
visit. cOnclusiOns: This study provided information to develop the medica-
tion safety policies, which some drugs should be monitored for severe allergic 
reactions.To increase patient safety and reduce costs arising from the treatment 
of those severe allergic reactions,the pharmacists should counsel and educate 
patients to the level that those patients can be able to observe themselves.
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Objectives: It is well known that the patients treated with fixed combination 
of inhaled corticosteroid/long acting beta-2 agonist(ICS/LABA) shows pneumonia 
as an adverse event. The purpose of this study is to compare the risk of hospi-
talization by pneumonia between two different ICS/LABA substances. MethOds: 
Retrospective cohort study was conducted using 2013 HIRA-NPS(National Patients 
Sample of Health Insurance Review and Assessment Service) database of Korea. The 
cohort consisted of the patients who were prescribed DPI(Dried Powder Inhaler) 
form of fluticasone/salmeterol and budesonide/formoterol at least once as an ini-
tial user from Feb 2013 to Dec 2013. The patients who were enrolled to the cohort 
was observed until the first hospitalization due to pneumonia(J12-18 of ICD-10 
code) occurrence. The incidence rate of pneumonia were estimated and crude and 
adjusted hazard ratio of pneumonia associated with ICS/LABA use with 95% confi-
dence intervals were estimated by Cox proportional hazard model. Results: The 
cohort included 5,939 patients of which 4,531 patients(76.3%) treated with fluti-
casone/salmeterol and 1,408 patients(23.7%) treated with budesonide/formoterol. 
The pneumonia incidence rate was higher with fluticasone/salmeterol which was 
8.50 per 100 person-year while the pneumonia incidence rate of budesonide/for-
moterol was 5.14 per 100 person-year. Compared with budesonide/formoterol, the 
pneumonia risk was higher in patients treated with fluticasone/salmeterol(hazard 
ratio: 1.48, 95% CI: 1.06-2.06). The results were similar in sensitivity analysis which 
regulated definition of initial users. cOnclusiOns: The higher risk of pneumonia 
occurrence was observed for fluticasone/salmeterol which shows the intra-class 
difference of fixed combination of inhaled corticosteroid/long acting beta-2 agonist. 
The difference between the adverse event occurrences should be considered before 
selection of drugs for the patients.
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